Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study

Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study

The treatment of multidrug‐resistant (MDR) chronic hepatitis B (CHB) is challenging. Herein, we report a multicenter prospective cohort study for the evaluation of tenofovir disoproxil fumarate (TDF)‐based therapy for MDR CHB in a real‐life setting. The inclusion criteria comprised patients with res...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of viral hepatitis 2020-12, Vol.27 (12), p.1306-1318
Hauptverfasser: Yim, Hyung Joon, Suh, Sang Jun, Jung, Young Kul, Hwang, Seong Gyu, Seo, Yeon Seok, Um, Soon Ho, Lee, Sae Hwan, Kim, Young Seok, Jang, Jae Young, Kim, In Hee, Kim, Hyoung Su, Kim, Ji Hoon, Lee, Young Sun, Yoon, Eileen L., Song, Myeong Jun, Park, Jun Yong
Format: Artikel
Sprache:eng
Schlagworte:
Adefovir
Antiretroviral drugs
chronic hepatitis B
Cirrhosis
Cohort analysis
Combination therapy
Deoxyribonucleic acid
DNA
Drug resistance
Hepatitis B
Interferon
Liver cirrhosis
multidrug resistance
Multidrug resistant organisms
Tenofovir
therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The treatment of multidrug‐resistant (MDR) chronic hepatitis B (CHB) is challenging. Herein, we report a multicenter prospective cohort study for the evaluation of tenofovir disoproxil fumarate (TDF)‐based therapy for MDR CHB in a real‐life setting. The inclusion criteria comprised patients with resistance to more than two nucleos(t)ide analogue (NA) classes and hepatitis B virus (HBV) DNA level of ≥200 IU/mL. The primary end‐point was virologic response (VR), defined as undetectable HBV DNA (
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.13363